Epidemiological study indicates a link between blood IGF-1 levels and the incidence of prostate, breast, and colon cancers [37], raising questions about the safety of long-term GH replacement in the event of de novo neoplasia, tumor regrowth, or tumor recurrence. This evidence concerns the gene IGF1 and neoplasm.